Evidence map›Paper›PMID 40551262›Full record

ReviewBiomarker research2025

Circulating tumor DNA for MRD detection in colorectal cancer: recent advances and clinical implications.

Dening Ma, Xinyi Gao, Li Wang, Huan Yin, Longhai Feng, Yuping Zhu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Liquid biopsy in modern medicine: advancing diagnostics from molecular insights to clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Review
  4. Association of ctDNAJournal of gastrointestinal oncology · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dening Ma *Department of Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Xinyi Gao *Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
Li WangGeneplus-Beijing Institute, Beijing, 102206, China.
Huan YinGeneplus-Beijing Institute, Beijing, 102206, China.
Longhai FengDepartment of Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Yuping ZhuDepartment of Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou, 310022, China. drzyp@163.com.

Funding

Medical Science and Technology Project of Zhejiang Province 2024KY044Natural Science Foundation of Zhejiang Province LY24H160020
6 · The paper itself

Abstract

Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) provides a powerful approach to predict recurrence in colorectal cancer (CRC) and potentially improve survival outcomes for individuals diagnosed with CRC. Currently, there are two primary technical approaches for the detection of MRD using ctDNA: the tumor-informed assays and the tumor-agnostic assays. Multiple studies have demonstrated the role of MRD detection in CRC patients after radical therapy, including early relapse monitoring, molecular profiling, and treatment response prediction. Numerous interventional clinical trials based on ctDNA are underway to explore the value of MRD in optimizing adjuvant treatment decisions for patients with CRC. Once validated, ctDNA-MRD has the potential to impact current clinical treatment decisions. In this review, we summarize current techniques for detecting MRD based on ctDNA and review the data that have been collected to date on MRD detection in CRC patients who received curative-intent therapy. We also discuss prospective research of ctDNA MRD detection in this patient population and provide guidelines for the current and future use of MRD in clinical practice.

Indexed as

BiomarkerCirculating tumor DNAColorectal cancerMolecular residual disease

Identifiers

PMID40551262
PMCPMC12186373

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.